CA Patent

CA2046533C — Treatment of endometriosis

Assigned to Tanabe Pharma Corp · Expires 1996-09-24 · 30y expired

What this patent protects

Disclosed is a use of danazol for vaginal administration in a form of powder, tablet, suppository, capsule or liquid, or for parenteral and non-vaginal administration in a form of a solution, the content or concentration of danazol is specified.

USPTO Abstract

Disclosed is a use of danazol for vaginal administration in a form of powder, tablet, suppository, capsule or liquid, or for parenteral and non-vaginal administration in a form of a solution, the content or concentration of danazol is specified.

Drugs covered by this patent

Patent Metadata

Patent number
CA2046533C
Jurisdiction
CA
Classification
—
Expires
1996-09-24
Drug substance claim
No
Drug product claim
No
Assignee
Tanabe Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.